Jennifer Alfano
Adult Health · Smithtown, NYNPI 1891120572
Payments from drug & device makers
Across 361 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$851
- GSK$802
- AbbVie$800
- Novo Nordisk$795
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$575
- Pfizer$503
- plus $4K from 31 others
What the payments were for
- Food & beverage$7,901100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $851 |
| GSK | 36 | $802 |
| AbbVie | 39 | $800 |
| Novo Nordisk | 37 | $795 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $575 |
| Pfizer | 27 | $503 |
| Sumitomo Pharma America, Inc. | 14 | $454 |
| Amgen | 11 | $422 |
| Amarin Pharma, Inc. | 19 | $409 |
| Lilly USA, LLC | 16 | $377 |
| Merck | 13 | $250 |
| Novartis | 11 | $242 |
| Kowa Pharmaceuticals America, Inc. | 14 | $232 |
| Exact Sciences | 7 | $171 |
| Astellas Pharma US Inc | 6 | $141 |
| Radius Health, Inc. | 5 | $128 |
| Johnson & Johnson | 8 | $123 |
| Daiichi Sankyo Inc. | 4 | $80 |
| Bayer | 3 | $70 |
| Boston Scientific | 1 | $51 |
| Avvisto Therapeutics, LLC | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Neurelis, Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Heartflow, Inc. | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $22 |
| Phadia US Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,901 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 77 | $98,220 |
| EliquisApixaban | 67 | $92,776 |
| MounjaroTirzepatide | 55 | $76,212 |
| OzempicSemaglutide | 42 | $70,478 |
| XareltoRivaroxaban | 37 | $52,131 |
| JardianceEmpagliflozin | 28 | $38,106 |
| RybelsusSemaglutide | 15 | $33,243 |
| EntrestoSacubitril/Valsartan | 17 | $33,192 |
| ProliaDenosumab | 17 | $28,987 |
| JanuviaSitagliptin Phosphate | 19 | $28,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $23,908 |
| LinzessLinaclotide | 20 | $21,676 |
| VascepaIcosapent Ethyl | 34 | $20,553 |
| WegovySemaglutide | 14 | $18,021 |
| MyrbetriqMirabegron | 19 | $17,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $795 | $121,74171 claims |
| AstraZenecaFarxiga | $851 | $98,22077 claims |
| PfizerEliquis | $503 | $92,77667 claims |
| Lilly USA, LLCMounjaro | $377 | $76,21255 claims |
| Johnson & JohnsonXarelto | $123 | $52,13137 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $802 | $38,93736 claims |
| Boehringer IngelheimJardiance | $29 | $38,10628 claims |
| NovartisEntresto | $242 | $33,19217 claims |
| AmgenProlia | $422 | $28,98717 claims |
| MerckJanuvia | $250 | $28,03919 claims |
| AbbVieLinzess, Synthroid | $800 | $22,64662 claims |
| Astellas Pharma US IncMyrbetriq | $141 | $17,80919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Smithtown
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.